Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLAD: Efgartigimod PH20 SC in Bullous Pemphigoid
jRCT2011220047Phase 3Completed
- Sponsor
- argenx
- Start
- May 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Efgartigimod PH20 SC arm with Placebo arm (2 arms). Started May 2023; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2011220047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220047.